BPCIA Litigation Roundup (Fall 2017)

AbbVie v. Amgen (adalimumab)  •  AbbVie v. Boehringer Ingelheim (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Coherus (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Mylan (pegfilgrastim)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Genentech v. Amgen (bevacizumab)  •  Genentech v. Pfizer (trastuzumab)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  Janssen v. Samsung Bioepis (infliximab)

Below is our fall update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, Fall 2016, Midwinter 2017, Spring 2017, Summer 2017).

Biosimilars to Neupogen® (filgrastim)

1) Amgen v. Sandoz

  • Accused Product: Zarxio® (filgrastim-sndz) [EP 2006]
  • Approval/Launch Status: FDA approved Sandoz’s aBLA on March 6, 2015. Sandoz launched on September 3, 2015.
  • Procedural History and Case Status:
    • District Court (No. 3:14-cv-04741-RS (N.D. Cal.)): On October 24, 2014, Amgen filed a complaint alleging that Sandoz had violated the BPCIA (1) by not providing its application and manufacturing information within 20 days of FDA acceptance as “required” under the first step of the patent dance set forth in subsection (l)(2)(A) of the BPCIA, and (2) by providing a purported notice of commercial marketing under subsection (l)(2)(A) of BPCIA before FDA had approved the application. Amgen asked the court to order Sandoz to follow the pathway set out in the BPCIA. On March 19, 2015, the District Court issued an order ruling in favor of Sandoz that the patent dance steps are not mandatory, and that biosimilar applicants do not have to wait for FDA approval before they can provide sufficient notice of commercial marketing. Amgen appealed (as discussed below). Meanwhile, the litigation on the merits is proceeding in the district court.  The case is being coordinated for discovery and trial with the Amgen v. Sandoz pegfilgrastim matter. In July 2017, the district court declined to stay discovery on the expected approval, marketing, and sales of Sandoz’s proposed pegfilgrastim product.  In October 2017, Sandoz moved for summary judgment of non-infringement and of no lost-profit damages.  A jury trial is scheduled for March 26, 2018.
    • Court of Appeals (No. 15-1499 (Fed. Cir.)): On July 21, 2015, the Federal Circuit, in a split panel decision, ruled: (1) in Sandoz’s favor (affirming the District Court) that the disclosures set forth in subsection (l)(2)(A) of the BPCIA are not mandatory and that the statute allows a biosimilar applicant to choose between either disclosing its subsection (k) application and manufacturing information, or not disclosing such information and instead facing an immediate infringement action from the reference product sponsor; and (b) in Amgen’s favor (reversing the District Court) that a notice of commercial marketing pursuant to subsection (l)(9)(A) of the BPCIA can be given only after FDA approval of the biosimilar product. In light of its interpretation of the “notice of commercial marketing” provision and its ruling in favor of Amgen, the Federal Circuit extended the injunction against Sandoz through September 2, 2015 (180 days after Sandoz received approval and provided an effective post-licensure notice of commercial marketing). On July 26, 2017, after the Supreme Court vacated the Federal Circuit’s decision and remanded for reconsideration of whether an injunction under state law can force compliance with the patent dance provisions of the BPCIA (as discussed below), the Federal Circuit vacated its prior opinion and ordered the parties to file supplemental briefing.  On August 28, 2017, the parties submitted supplemental briefs, which were followed by amicus briefs by the Biosimilars Council and the United States.
    • Supreme Court (Nos. 15-1039 and 15-1195): On February 16, 2016, Sandoz filed a petition for certiorari, asking the Supreme Court to review the Federal Circuit’s interpretation of the BPCIA’s “notice of commercial marketing” provision. On March 21, 2016, Amgen opposed Sandoz’s petition and also filed a conditional cross-petition for certiorari, challenging the Federal Circuit’s ruling that a biosimilar applicant is not required by the BPCIA to disclose a copy of its aBLA and related manufacturing information. On January 13, 2017, the Supreme Court granted both cert petitions, and on April 26, 2017, held oral argument. On June 12, 2017, the Supreme Court issued its opinion, holding that notice of commercial marketing may be given prior to FDA approval and that no injunction is available under federal law to force compliance with the patent dance. The Court declined to resolve, and remanded to the Federal Circuit, the question of whether an injunction might be available under state law, but questioned whether such a state-law injunction might be preempted by federal law.

2) Amgen v. Apotex

  • Accused Product: Grastofil™ (filgrastim)
  • Approval/Launch Status: Not licensed. FDA accepted Apotex’s aBLA in February 2015.
  • Procedural History and Case Status:
    • District Court (No. 15-62081-JIC (S.D. Fla.)): BPCIA complaint filed October 2, 2015. In November 2015, the case was consolidated into the Amgen v. Apotex pegfilgrastim litigation, where the district court entered judgment of non-infringement with respect to Apotex’s filgrastim and pegfilgrastim products. Amgen has appealed. See the summary below of the Amgen v. Apotex pegfilgratim litigation for more details.
    • Court of Appeals (No. 17-1010 Fed. Cir.): See the summary below of the Amgen v. Apotex pegfilgratim litigation for more details.

Biosimilars to Neulasta® (pegfilgrastim)

1) Amgen v. Sandoz

  • Accused Product: LA-EP2006 (pegfilgrastim)
  • Approval/Launch Status: Not licensed. FDA accepted Sandoz’s aBLA in November 2015. In July 2016, FDA issued a Complete Response Letter. Sandoz does not expect to submit data to FDA in response until Q1 2019.
  • Procedural History and Case Status:
    • District Court
      • (No. 16-1276-SRC-CLW (D.N.J.)): On March 4, 2016, Amgen filed a complaint against Sandoz seeking a declaratory judgment that Sandoz violated the BPCIA by attempting to unilaterally waive steps of the patent dance. Sandoz later restarted the patent dance negotiations, and this complaint was dismissed.
      • (No. 3:16-cv-02581-RS (N.D. Cal.)): BPCIA complaint filed on May 13, 2016. The case is being coordinated for discovery and trial with the Amgen v. Sandoz filgrastim matter.

2) Amgen v. Apotex

  • Accused Product: Lapelga™ (pegfilgrastim)
  • Approval/Launch Status: Not licensed. FDA accepted Apotex’s aBLA in December 2014. Prior to the Supreme Court’s decision in Amgen v. Sandoz, Apotex was enjoined by the district court from launching its product until 180 days after it provides an effective, post-licensure notice of commercial marketing.
  • Procedural History and Case Status:
    • District Court (No. 15-61631-JIC (S.D. Fla.)): BPCIA complaint filed August 6, 2015. In November 2015, the Amgen v. Apotex filgrastim litigation (discussed above) was consolidated into this case. On December 10, 2016, the district court preliminarily enjoined Apotex from launching its pegfilgrastim biosimilar product until 180 days after it provides a post-licensure notice of commercial marketing. After holding a bench trial in July 2016, the district court (1) granted Amgen’s motion for judgment on partial findings with respect to each of Apotex’s invalidity defenses except for non-enablement, (2) entered judgment of non-infringement in Apotex’s favor, and (3) reserved judgment on Apotex’s non-enablement defense by dismissing Apotex’s invalidity counterclaim without prejudice. The patent-in-suit is also the subject of a pending IPR petition.
    • Court of Appeals:
      • (No. 16-1308 Fed. Cir.): Apotex appealed from the District Court’s grant of a preliminary injunction. On July 5, 2016, the Federal Circuit affirmed the District Court’s ruling, and, on August 11, 2016, issued its mandate. Apotex filed a petition for certiorari, which was denied (as discussed below).
      • (No. 17-1010 Fed. Cir.): On October 3, 2016, Amgen filed a notice of appeal to the Federal Circuit from the District Court’s judgment of non-infringement. The Court heard oral argument on October 3, 2017.  On November 13, 2017, a Federal Circuit panel affirmed the district court’s judgment in favor of Apotex.
    • Supreme Court (No. 16-332): On September 9, 2016, Apotex filed a petition for certiorari, asking the Supreme Court to review the Federal Circuit’s application of its Amgen v. Sandoz decision to Apotex, as well as its interpretation of the BPCIA’s “notice of commercial marketing” provision. The Biosimilars Council and Mylan filed amicus briefs in support of Apotex. Briefing on the petition concluded on November 21, 2016. On December 12, 2016, the Supreme Court denied Apotex’ petition.

3) Amgen v. Coherus

  • Accused Product: CHS-1701 (pegfilgrastim)
  • Approval/Launch Status: Not licensed. FDA accepted Coherus’ aBLA in October 2016, but issued a Complete Response Letter in June 2017.
  • Procedural History and Case Status:
    • District Court (No. 17-546-LPS-CJB (D. Del.)): BPCIA complaint filed May 10, 2017. Amgen alleges infringement of one patent. Coherus moved to stay discovery in the case, but subsequently withdrew the motion.  The court has scheduled a 5-day jury trial for September 16, 2019.

4) Amgen v. Mylan

  • Accused Product: MYL-1401H (pegfilgrastim)
  • Approval/Launch Status: Not licensed. FDA accepted Mylan’s aBLA in February 2017, but issued a Complete Response Letter in October 2017.
  • Procedural History and Case Status:
    • District Court (No. 17-1235-MRH (W.D. Pa.)): BPCIA complaint filed September 22, 2017. Amgen alleges infringement of two patents. Mylan answered the complaint on November 22, 2017.

Biosimilars to Remicade® (infliximab)

1) Janssen v. Celltrion

  • Accused Product: Inflectra® (infliximab-dyyb) [CT-P13]
  • Approval/Launch Status: FDA approved Celltrion’s aBLA on April 5, 2016. Celltrion and Hospira launched in late 2016.
  • Procedural History and Case Status:
    • District Court
      • (Janssen v. Celltrion, No. 15-10698-MLW (D. Mass.)): BPCIA complaint filed March 6, 2015. On May 21, 2016, the District Court denied a motion by Janssen to stay the litigation, but granted Janssen’s motion to amend the protective order to permit it to file a new case against HyClone, the third-party cell culture media supplier for Celltrion’s biosimilar product, based on information produced by Celltrion under the protective order. In August 2016, the District Court granted Celltrion’s motion for summary judgment that all claims of the ’471 patent are invalid for obviousness-type double patenting, based on multiple reference patents. On September 26, 2016, the District Court entered partial final judgment of invalidity with respect to the ’471 patent, and Janssen has appealed to the Federal Circuit. The defendants moved for summary judgment of non-infringement of the ’083 patent, the sole remaining patent-in-suit. On December 22, 2016, the district court denied the summary judgment motion as to Celltrion, but requested additional briefing with respect to Hospira. On February 22, 2017, Celltrion moved to dismiss for lack of standing to bring the suit, a motion which the parties recently completed briefing. On March 3, 2017, the court issued a memorandum and order providing guidance regarding the standards for determining damages in the litigation. The original jury trial date of February 13, 2017 has been postponed. This case has been dismissed without prejudice, in favor of the new action, Civil Action No. 17-11008, discussed below.
      • (Janssen v. Celltrion, No. 16-11117-MLW (D. Mass.)): Complaint filed June 14, 2016 for infringement of ’083 patent based on cell culture media. This action is consolidated into the 15-10698 action. This case has been dismissed without prejudice, in favor of the newly filed action, Civil Action No. 17-11008, discussed below.
      • (Janssen v. HyClone, No. 16-00071-BCW (D. Utah): Complaint filed June 14, 2016 for infringement of ’083 patent based on cell culture media. On August 5, 2016, HyClone moved to dismiss the complaint and stay the litigation. This case has been stayed pending resolution of the D. Mass. cases.
      • (Janssen v. Celltrion, No. 17-11008-MLW (D. Mass.)): Complaint filed May 31, 2017 for infringement of ’083 patent, after Celltrion allegedly attempted to reengage in negotiations under 42 U.S.C. § 262(l)(4). The prior D. Mass. litigations (15-10698 and 16-11117) were dismissed without prejudice in favor of this action. On October 31, 2017, the district court denied Celltrion’s motion to dismiss for lack of standing, but Celltrion has sought leave of court to file an interlocutory appeal of that ruling.  Celltrion has asked the Court to schedule trial in September 2018, whereas Janssen is seeking a trial in May 2018.
    • Court of Appeals:
      • (No. 17-1120 Fed. Cir.): On October 24, 2016, Janssen filed a notice of appeal to the Federal Circuit from the District Court’s partial final judgment of invalidity with respect to the ’471 patent, based on double patenting. The parties completed briefing in April 2017. This appeal is being treated as a companion case for oral argument purposes with Janssen’s related appeal (No. 17-1257) from an ex parte reexamination ruling by the USPTO that the ’471 patent’s claims are unpatentable for double patenting. Briefing in that appeal concluded on June 6, 2017. The Court heard oral argument on October 3, 2017 but has not yet issued a decision.

2) Janssen v. Samsung Bioepis

  • Accused Product: Renflexis® (infliximab-abda) [SB2]
  • Approval/Launch Status: FDA approved Samsung Bioepis’s aBLA on April 21, 2017. Samsung Bioepsis launched around July 26, 2017.
  • Procedural History and Case Status:
    • District Court (No. 17-3524-MCA-SCM (D.N.J.)): BPCIA complaint filed May 17, 2017. Janssen’s complaint alleged (a) infringement by Samsung Bioepis of three patents, including the ’083 patent, which is also in suit in the Janssen v. Celltrion case, and (b) violations by Samsung Bioepis of the BPCIA (1) by refusing to produce its aBLA or engage in the patent dance, and (2) by providing a purported “notice of commercial marketing” prior to receiving FDA approval.  After withdrawing its BPCIA violation claims as moot in September 2017, Janssen voluntarily dismissed its patent infringement claims on November 10, 2017.

Biosimilars to Epogen®/Procrit® (epoetin alfa)

1) Amgen v. Hospira

  • Accused Product: Retacrit™ (epoetin alfa)
  • Approval/Launch Status: Not licensed. In October 2015, FDA issued a Complete Response Letter. In December 2016, Hospira resubmitted its aBLA. Although FDA’s Oncologic Drugs Advisory Committee recommended approval of the product across all indications on May 25, 2017, FDA subsequently issued a second Complete Response Letter in connection with the aBLA.
  • Procedural History and Case Status:
    • District Court (No. 15-839-RGA (D. Del.)): BPCIA complaint filed September 18, 2015. In May 2016, the District Court denied Amgen’s motion to compel Hospira to produce manufacturing information and correspondence with FDA, finding that Amgen had not shown that the information sought was relevant to the charges of infringement of the asserted patents. On August 5, 2016, the District Court denied a motion by Hospira to dismiss count I of Amgen’s complaint regarding Hospira’s alleged failure to comply with the BPCIA’s notice of commercial marketing provision. On October 3, 2016, the District Court issued an order granting-in-part and denying-in-part a motion by Amgen to amend its complaint. On May 26, 2017, Amgen moved for a preliminary injunction to enjoin Hospira from launching its biosimilar “until Hospira has complied with the requirement of 42 U.S.C. § 262(l)(8)(A),” but withdrew the motion on July 12, 2017. Prior to trial, the district court denied Hospira’s motion for summary judgment of non-infringement.  In September 2017, the case was tried to a jury, which (1) found that Hospira’s manufacture of 14 of 21 accused batches of drug substance infringed one of the patents-in-suit, (2) found that the infringed patent was not invalid, and (3) awarded Amgen $70 million in damages.  Hospira has since moved for judgment as a matter of law of, among other things, no infringement, and Amgen has filed its own motion seeking judgment as a matter of law of infringement of the patent the jury found was not infringed.  The parties are scheduled to complete briefing on December 8, 2017.
    • Court of Appeals (No. 16-2179 (Fed. Cir.)): Amgen appealed from the denial of its motion to compel. On August 12, 2016, the Federal Circuit denied a motion by Hospira to dismiss Amgen’s appeal and ordered the parties to address both the merits of the discovery dispute and the issue of jurisdiction in their briefs. The parties completed briefing the appeal in November 2016, and the Federal Circuit held oral argument on April 3, 2017. On August 10, 2017, the Federal Circuit dismissed Amgen’s appeal.

Biosimilars to Enbrel® (etanercept)

1) Immunex v. Sandoz

  • Accused Product: Erelzi™ (etanercept-szzs) [GP2015]
  • Approval/Launch Status: FDA approved Sandoz’s aBLA on August 30, 2016. Sandoz has agreed not to launch its biosimilar until a time point that has not been publicly disclosed.
  • Procedural History and Case Status:
    • District Court (No. 16-01118-CCC-JBC (D.N.J.)): BPCIA complaint filed February 26, 2016. On August 11, 2016, the District Court entered a scheduling order and a consent preliminary injunction that enjoins Sandoz from making, using, importing, offering to sell, or selling its product, “except as allowed by 35 U.S.C. § 271(e)(1).” Amgen has moved for summary judgment of infringement.  A trial is set for April 17, 2018.

Biosimilars to Humira® (adalimumab)

1) AbbVie v. Amgen

  • Accused Product: Amjevita™ (adalimumab-atto) [ABP 501]
  • Approval/Launch Status: FDA approved Amgen’s aBLA on September 23, 2016. Amgen has indicated that it expects to launch on January 31, 2023.
  • Procedural History and Case Status:
    • District Court (No. 16-666-MSG (D. Del.)): BPCIA complaint filed August 4, 2016. AbbVie asserted 10 patents as part of the first wave litigation but, according to its complaint, had identified 51 other patents that it could assert against Amgen in a second wave litigation. On September 28, 2017, Amgen announced that it had settled this litigation and expected to launch Amjevita™ in the United States on January 31, 2023.

2) AbbVie v. Boehringer Ingelheim

  • Accused Product: Cyltezo™ (adalimumab-adbm) [BI 695501]
  • Approval/Launch Status: FDA approved BI’s aBLA on August 26, 2017. BI has not yet launched.
  • Procedural History and Case Status:
    • District Court (No. 17-1065-SLR (D. Del.)): BPCIA complaint filed August 2, 2017. AbbVie is asserting 8 patents as part of the first wave litigation but, according to its complaint, has identified 66 other patents that it could assert against BI in a second wave litigation. The court has entered a scheduling order under which expert discovery will close on May 29, 2020, and the court will hold an in-person status conference on June 4, 2020, during which a schedule for dispositive motions and trial will be discussed.

Biosimilars to Avastin® (bevacizumab)

1) Genentech v. Amgen and Amgen v. Genentech

  • Accused Product: Mvasi™ (bevacizumab-awwb) [ABP 215]
  • Approval/Launch Status: FDA approved Amgen’s aBLA on September 14, 2017. Amgen has not yet launched.
  • Procedural History and Case Status:
    • District Court
      • (Genentech v. Amgen, No. 17-165-GMS (D. Del.)): On February 15, 2017, Genentech filed a complaint for declaratory judgment against Amgen alleging certain violations of the patent dance provisions of the BPCIA following FDA’s acceptance of Amgen’s aBLA. On March 1, 2017, the court dismissed Genentech’s complaint without prejudice. On April 17, 2017, Amgen represented that “the parties are now moving through the ‘patent dance’ as contemplated under the BPCIA.”
      • (Amgen v. Genentech, No. 17-7349-GW-AGR (C.D. Cal.)): On October 6, 2017, Amgen filed a complaint for declaratory judgment against Genentech of non-infringement, invalidity and/or unenforceability of the 27 patents that Genentech had allegedly listed on its (l)(3)(A) list.  Genentech has moved to dismiss this complaint.
      • (Genentech v. Amgen, No. 17-1407-GMS (D. Del.)): On October 6, 2017, Genentech filed a complaint for patent infringement under the BPCIA against Amgen, alleging infringement of 24 patents (all of which were included in Amgen’s complaint). Amgen have moved to transfer the case to the Central District of California.
      • (Genentech v. Amgen, No. 17-1471-GMS (D. Del.)): On October 18, 2017, Genentech filed a second complaint for patent infringement under the BPCIA against Amgen, alleging infringement of 25 patents (adding one additional patent to the previously asserted 24 patents). Amgen have moved to transfer the case to the Central District of California.

Biosimilars to Herceptin® (trastuzamab)

1) Genentech v. Pfizer 

  • Accused Product: PF-05280014 (trastuzumab)
  • Approval/Launch Status: Not licensed.  FDA allegedly accepted Pfizer’s aBLA for review on August 21, 2017.
  • Procedural History and Case Status:
    • District Court: (No. 17-1672-VAC-SRF (D. Del.)): BPCIA complaint filed November 17, 2017. Genentech is alleging infringement of 40 patents.  Pfizer’s answer to the complaint is due December 11, 2017.
Download PDF

Tagged with 

Comments are closed.